Polatuzumab vedotin (Polivy®). HTA ID: 22043
Polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
| NCPE Assessment Process | Complete |
| Rapid review commissioned | 27/06/2022 |
| Rapid review completed | 27/07/2022 |
| Rapid Review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pola-R-CHP compared with the current standard of care. |